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Abstract
CD4+ memory T cells (Tm) from rheumatoid arthritis peripheral blood (RAPB) or peripheral blood from
normal donors produced IL-2, whereas fewer cells secreted IFN-g or IL-4 after a brief stimulation.
RAPB Tm contained significantly more IFN-g producers than normal cells. Many rheumatoid arthritis
(RA) synovial Tm produced IFN-g alone (40%) and fewer cells produced IL-2 or IL-4. An in vitro model
was employed to generate polarized T-helper (Th) effectors. Normal and RAPB Tm differentiated into
both IFN-g- and IL-4-producing effectors. RA synovial fluid (RASF) Tm demonstrated defective
responsiveness, exhibiting diminished differentiation of IL-4 effectors, whereas RA synovial tissue
(RAST) Tm exhibited defective generation of IFN-g and IL-4 producers.
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Introduction
RA is an autoimmune disease that is characterized by per-
sistent local and systemic inflammation [1–3]. Aggressive
forms of RA are thought to be driven by T-lymphocyte
activity, leading to the rapid erosion of bone and cartilage.
Activated Tm are found in the perivascular regions of the
inflamed synovium, and T cells accumulate in the synovial
fluid [4–6]. It appears that memory T cells retain the
potential to traffic through the synovium and lymphatics
and recirculate in the blood, as evidenced by the
increased numbers of activated memory T cells found in
the blood of some RA patients [6–8]. It is not known,
however, whether Tm migrate into the synovium and
undergo activation and further differentiation, or whether
activation occurs in regional lymph nodes before migration
into the inflammatory site.
In vitro studies [9,10] have demonstrated that synovial
CD4+ T cells proliferate poorly and produce decreased
levels of IL-2 in response to mitogen or antigen, as com-
pared with peripheral blood T cells from healthy individu-
als or RA patients. Although such findings suggest thatAvailable online http://arthritis-research.com/content/3/1/054
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synovial T cells might be partly anergic, more recent
studies have indicated that the T cells found in the RA syn-
ovium were postactivated cells. Synovial T cells were acti-
vated as assessed by expression of CD40 ligand/CD154,
and were also efficient helpers for B-cell immunoglobulin
production [9–13]. Previous studies in animal models
[14,15] suggested that a balance exists between
immunoregulatory IFN-g-producing Th1 cells and IL-4-pro-
ducing Th2 cells. Dominance of either subset can result in
a chronic disease state. Moreover, induction of Th2 cells
in a Th1-mediated disease model of collagen-induced
arthritis led to amelioration of autoimmune disease [16].
Thus, it is possible that, in RA, there is biased differentia-
tion of IFN-g-secreting proinflammatory Th1 CD4+ T cells,
and insufficient differentiation of immunoregulatory IL-4-
producing Th2 cells.
Human memory T cells acquire the ability to secrete IL-4
late during in vivo differentiation. Our previous studies and
work by others have demonstrated that most of the in vivo
differentiated IL-4-producing T cells reside within the
mature memory (CD45RO+,CD27–) subset of CD4+
T cells [17–19]. Thus, early memory (CD45RO+,CD27+)
CD4+ T cells cannot secrete IL-4 after a brief in vitro stim-
ulation. Previous studies [17,18] suggested that early
memory T cells represent an uncommitted precursor pop-
ulation, from which both IL-4-producing and IFN-g-produc-
ing effector cells can be generated. The RA synovium
appears to contain an increased number of phenotypically
mature memory T cells as compared with the blood.
However, the majority of memory T cells found in the syn-
ovium bear the phenotype of early Tm [7].
Therefore, the present study was undertaken to examine
the cytokine effector status of synovial memory T cells and
the functional status of immature memory cell precursors
of cytokine-producing effector cells. For these experi-
ments, Tm were isolated from the blood of normal sub-
jects, and from RAPB, RASF and RAST. Intracellular
cytokine expression was assessed by flow cytometry
immediately after isolation and a brief in vitro stimulation,
or after in vitro priming designed to generate IL-4-produc-
ing effector T cells.
The results suggest that a deficiency in the generation of
adequate numbers of regulatory IL-4-producing effector
cells in the synovium might be a contributing factor to the
perpetuation of chronic inflammation.
Materials and methods
Antibodies and reagents
MAbs used included the following: anti-CD3 (OKT3; Amer-
ican Type Culture Collection, Rockville, MD, USA), anti-
CD8 (OKT8; American Type Culture Collection), anti-CD16
(B73.1; generous gift of Dr G Trinchieri, The Wistar Insti-
tute, Philadelphia, PA, USA), anti-CD19 (Dako, Glostrup,
Denmark), anti-CD45RO (UCHL1; Dako), and anti-
CD45RA (2H4; gift of Dr C Morimoto, Boston, MA, USA)
[17,18]. Anti-CD28 (28.2), Phycoerythrin (PE)-labeled anti-
IL-2, PE-labeled anti-IL-4, and fluorescein isothiocyanate
(FITC)-labeled anti-IFN-g was from Pharmingen (San
Diego, CA, USA). FITC-labeled anti-CD3, and PE-labeled
or Quantum red-labeled anti-CD4 was from Sigma (St
Louis, MO, USA). Recombinant IL-4 and recombinant IL-15
were from R&D Systems (Minneapolis, MN, USA). Neutral-
izing antihuman IFN-g antibody was from Endogen (Cam-
bridge, MA, USA). Culture medium contained RPMI 1640
with penicillin G (200U/ml), gentamicin (10mg/ml), L-gluta-
mine (0.3mg/ml), and 10% normal human serum [17].
Patients
All patients had an established diagnosis of RA, as defined
by the 1987 revised criteria of the American College of
Rheumatology for the classification of RA. All patients had
long-standing, active RA. All samples were obtained after
informed consent, as approved by the UT Southwestern
Institutional Review Board. The data shown were obtained
from 14 RA patients (age range 29–78 years). Matching
blood and synovial fluid were obtained from six patients.
Peripheral blood alone was obtained from one patient and
synovial fluid samples were obtained from three patients.
Matching blood and synovial tissue samples were obtained
from three patients at the time of surgery. An additional
synovial tissue sample was obtained from one patient.
Cell preparation
Mononuclear cells were isolated from synovial tissue by
treating the synovial tissue with collagenase briefly at
37°C with constant shaking. The cells were washed, fil-
tered through nylon mesh, and briefly adhered to plastic
petri dishes at 37°C to deplete residual fibroblast and
monocytes [7,9]. Mononuclear cells were obtained from
blood or synovial samples of RA patients, or sex-matched
and age-matched healthy adult individuals by ficoll density
centrifugation. Cells were washed and incubated with
neuraminidase-treated sheep red blood cells, and purified
by negative selection panning as previously described
[17]. The cells were incubated with anti-CD8, anti-CD19,
B73.1, and 2H4 mAbs. After panning, the recovered cells
were routinely greater than 99% CD3+, 95% CD4+, and
90% enriched for CD45RO+ cells.
Cell culture
T cells were immediately stimulated after isolation with
ionomycin (0.5mM; Sigma), phytohemagglutinin (2mg/ml;
Wellcome Diagnostics, Greenville, NC, USA), and phorbol
myristate acetate (20ng/ml; Sigma) in the presence of
monensin (2mM; Sigma) for 6h and were fixed in
paraformaldehyde for subsequent intracellular cytokine
analysis. In some experiments, T cells were primed for
1 week before cytokine analysis [17]. T cells
(5×10 5 cells/ml) were cultured in 96-well plates (Costar,Arthritis Research    Vol 3 No 1 Davis et al
Cambridge, MA, USA). Where indicated, wells were
coated with anti-CD3 mAb (OKT3) before addition of
T cells. Medium contained 10U/ml recombinant IL-2,
5ng/ml recombinant IL-15, 50ng/ml recombinant IL-4,
anti-CD28 mAb (0.5mg/ml) and, where indicated, neutral-
izing anti-IFN-g antibody (5mg/ml). After 1 week in culture
the cells were harvested and counted. The cells were
washed, and incubated for 60h in medium containing IL-2
(10U/ml) and IL-15 (5ng/ml) before restimulation. In pre-
liminary experiments the presence of IL-4 during the rest
phase did not increase the number of IL-4-producing cells
detected on subsequent restimulation. Restimulation and
intracellular cytokine analysis were carried out as
described above for immediately stimulated T cells [17].
Flow cytometry
T cells (3×105) were stained with saturating amounts of
directly conjugated mAb and analyzed on the fluores-
cence-activated cell sorter (FACScan; Becton Dickinson,
San Jose, CA, USA). For intracellular staining of cytokines,
cells were stimulated as described above. The cells were
harvested, washed, fixed with paraformaldehyde, perme-
abilized with saponin, and blocked with rodent serum. The
cells were stained with directly conjugated mAbs to
human cytokines (Pharmingen) and analyzed by flow
cytometry [17]. Stimulated cells that were stained with
irrelevant mAbs were used as controls. Analysis was
carried out on 104 cells for each sample.
Statistical analysis
Statistically significant differences in the percentages of
cells that expressed each cytokine were determined using
the two-tailed Student’s t-test, or the Mann–Whitney Rank
Sum when appropriate. P<0.05 was considered statisti-
cally significant.
Results
Enrichment of IFN-g producers in freshly isolated RA
synovial CD4+ CD45RO+ T cells
Initial experiments delineated cytokine production by
freshly isolated CD4+ CD45RO+ T cells obtained from
matching samples of RAPB and RASF. A representative
sample is shown in Fig. 1 (RA patient 1). The majority of
peripheral blood T cells from RA patients secreted IL-2
alone, whereas fewer cells secreted IFN-g alone or in com-
bination with IL-2. By contrast, the CD4+ T cells isolated
from the synovial fluid demonstrated a significant increase
in the percentage of cells that produced IFN-g alone or in
combination with IL-2, whereas a decrease was observed
in the percentage of cells that secreted IL-2 alone. Few
cells from peripheral blood or synovial fluid produced IL-4.
Matching samples obtained from the peripheral blood and
synovial tissue of RA patients were also assessed for
cytokine expression (Fig. 1; RA patient 7). As was
observed in the synovial fluid, memory T cells isolated from
the synovial tissue contained a decreased percentage of
IL-2-producing cells and an increased percentage of
IFN-g-producing cells. Thus, T cells isolated from the
rheumatoid synovial tissue and fluid demonstrated a polar-
ized Th1 cytokine profile.
As a control, the cytokine profiles of Tm from normal adult
volunteers were examined (Fig. 1; normal 1). As observed
for blood from RA patients, the majority of cells produced
IL-2 alone, whereas fewer cells produced the combination
of IL-2 and IFN-g. Relatively infrequent cells expressed a
highly polarized phenotype by producing either IFN-g
alone or IL-4 alone.
A compilation of the frequency of cells that produced each
cytokine from a number of donors is shown in Fig. 2. After
a brief in vitro stimulation, the majority of Tm obtained from
normal donors (n=11) produced IL-2 alone (75±4%;
mean±SEM). Fewer cells produced the combination of
IL-2 and IFN-g (14±3%). Relatively infrequent cells
expressed a highly polarized phenotype by producing
either IFN-g (6±1%) or IL-4 alone (4±1%). Less than 1%
of the cells produced the combination of IFN-g and IL-4.
Cytokine secretion profiles of freshly isolated Tm obtained
from RAPB (n=9) also demonstrated that most secreted
IL-2 alone (75±3%), whereas fewer cells produced IL-2
in combination with IFN-g (8±1%). There was no signifi-
cant difference between the normal T cells and RA T cells
for these two groups. Of note, there was a significant
(P<0.05) increase in the percentage of cells that
secreted IFN-g alone compared with normal cells
(11±2% versus 6±1%), whereas there was no differ-
ence between normal blood and RAPB in the number of
cells that secreted IL-4 alone (4±1%) or in the frequency
of those rare cells that produced the combination of IL-4
and IFN-g (1±0%).
There was a significant decrease in the number of cells iso-
lated from RASF (n=8) that produced IL-2 alone (31±9%)
when compared with normal blood (P<0.001) or RAPB
(P<0.001) T cells. Moreover, an increase was observed in
the number of cells that secreted the combination of IL-2 and
IFN-g (27±3%), which was significantly greater than the per-
centage of the same subset in normal blood (P<0.01) or
RAPB (P<0.01). The percentage of RASF cells that pro-
duced IFN-g alone (41±8%) was also significantly increased
over the percentage of such cells in normal blood
(P<0.002) or RAPB (P<0.002) T cells. Significantly fewer
cells produced IL-4 alone (1±0%) as compared with normal
blood (P<0.05) or RAPB (P<0.05) T cells, whereas no sig-
nificant difference was observed in the number of cells that
produced the combination of IL-4 and IFN-g (2±0%).
RAST Tm (n=4) also contained a decreased percent-
age of IL-2-secreting cells (37±9%), which did notAvailable online http://arthritis-research.com/content/3/1/054
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differ significantly from that in the RASF, but did differ
significantly from that in normal blood (P<0.001) and
RAPB (P<0.001). The percentage of cells that pro-
duced both IFN-g and IL-2 (25±1%) did not differ sig-
nificantly from that in RASF, but was significantly
greater than the frequencies observed in normal blood
(P<0.05) or RAPB (P<0.05). In RAST, 34±9% of
cytokine effectors secreted IFN-g alone. This was not
different from the percentage found in RASF, but was
significantly greater than the percentage of IFN-g-pro-
ducing cells in normal blood (P<0.005) or RAPB
(P<0.005). There was no significant difference in the
number of synovial tissue cells that produced IL-4 alone
(2±1%) or IL-4 and IFN-g (2±0%), as compared with
RASF, normal blood or RAPB.
Thus, T cells isolated from RAST and RASF demonstrated
a decrease in IL-2-producing cells, with a concomitant
increase in IFN-g-producing cells when compared with
normal blood and RAPB Tm.
Figure 1
Representative cytokine profiles of Tm isolated from healthy donors and RA patients. CD4+,CD45RO+ T cells were isolated from the blood and
synovial fluid of an RA patient (RA Patient 1), the blood and synovial tissue of an RA patient (RA Patient 7), and the blood of a healthy donor
(Normal 1). Intracellular cytokines were assessed for peripheral blood and synovial cells from RA patients or blood of healthy donors. Cells were
briefly stimulated for 6 h, fixed, permeabilized and stained with directly labeled control antibodies or anti-IFN-g-FITC in combination with either PE-
labeled anti-IL-2 or PE-labeled anti-IL-4, as indicated on the axes; 104 cells were collected for each analysis. The numbers shown represent the
percentages of cells in each quadrant. Control staining with IgG-PE and IgG-FITC was carried out for each sample as shown (Normal 1) and the
background was subtracted. Samples were obtained from matching RA blood and synovial fluid (n=5), matching blood and synovial tissue (n=3),
and normal blood (n=11). Statistical analysis of all samples evaluated for intracellular cytokines immediately after isolation is shown in Fig. 2.Rheumatoid CD4+ T cells demonstrate defective
responsiveness to differentiation signals in vitro
Peripheral blood and synovial Tm were than examined in
an in vitro culture system in order to determine the relative
capacity of differentiation signals to modulate cytokine
production. Our previous studies with normal T cells [17]
demonstrated that this system effectively generates polar-
ized IFN-g-producing or IL-4-producing effector cells.
Fig. 3 shows the composite cytokine profiles of CD4+,
CD45RO+ T cells obtained from cultures primed with anti-
CD28 and cytokines in the absence or presence of anti-
CD3 mAb. As seen in Fig. 3, stimulation of normal T cells
after priming with anti-CD28 alone resulted in a significant
decrease in the percentage of IL-2 producers (35%
versus 75%) compared with cells immediately stimulated
after isolation, and a significant increase in the percent-
ages of IFN-g (31% versus 6%) and IL-4 producers (17%
versus 4%). After priming with a low dose of anti-CD3
(Fig. 3; middle panel), the percentage of IL-2 producers
decreased further and the percentage of IFN-g-secreting
cells increased. As previously shown, the generation of
IL-4-secreting cells was optimally induced by priming with
anti-CD28 alone and was inhibited by costimulation with
anti-CD3 mAb [17].
T cells derived from RAPB demonstrated a distinct pattern
of responsiveness. Whereas the percentage of IL-2-
secreting cells decreased after in vitro priming with anti-
CD28 as compared with freshly isolated cells (52%
versus 75%), a greater decrease was observed after
priming with low dose anti-CD3 (29%), and the cells were
resistant to further modulation by higher concentrations of
anti-CD3. Of note, the loss of IL-2 production by in vitro
primed RA T cells was less marked than observed with
normal T cells. An increased percentage of IFN-g produc-
ers was observed after priming, and the peak response
was achieved in the presence of low concentrations of
anti-CD3 (45% versus 11%). Again, the induction of IFN-g
production in RAPB memory T cells was less than noted in
normal blood. IL-4-producing cells were generated from
RA memory T cells by stimulation with anti-CD28, and
these were inhibited by the presence of anti-CD3 mAb.
The percentage of IL-4 producers (12%) generated from
RA memory T cells was less than was generated from
normal T cells (17%).
T cells from RASF primed with anti-CD28 exhibited a
decrease in the percentage of IL-2-producing cells (15%
versus 31%) and an increase in the percentage of IFN-g-
secreting cells (67% versus 41%) as compared with
freshly isolated cells. Synovial fluid T cells were deficient
in the ability to generate IL-4-producing cells (1%), which
was in contrast to the blood. Whereas RAPB T cells were
refractory to priming by high concentrations of anti-
CD3 mAb, the synovial fluid T cells responded to anti-CD3
in a dose-dependent manner. T cells derived from synovial
tissue were also relatively refractory to in vitro priming as
compared with normal blood T cells. Synovial tissue
T cells contained an increased percentage of IL-2 produc-
ers (48% versus 37%) and a small decrease in IFN-g pro-
ducers (23% versus 34%) after in vitro priming with
anti-CD28. Importantly, IL-4-secreting cells (8% versus
2%) could be generated from synovial tissue memory
T cells after in vitro differentiation, although in lesser
numbers than from RAPB and normal blood. Priming in
the presence of anti-CD3 reduced the percentages of
IL-2-producing and IL-4-producing cells, while increasing
the percentage of IFN-g-secreting cells.
Effect of anti-IFN-g g antibody on the generation of IL-4-
secreting effector cells from RA synovial fluid T cells
In order to determine whether cytokine production by
rheumatoid T cells was resistant to modulation in the in
Arthritis Research    Vol 3 No 1 Davis et al
Figure 2
Frequency of cytokine producing cells in Tm subsets. Intracellular
staining for cytokines was assessed for CD4+,CD45RO+ T cells that
were immediately stimulated after isolation as described in Fig. 1; 104
cells were collected for each analysis of normal blood (n=11), RAPB
(n=9), RASF (n=8), and RAST (n=4). The total number of cytokine-
producing cells detected in each sample is shown in the upper right
corner of each graph. The frequency of each subset of cytokine-
producing cells is shown (mean±standard error of the mean). The
frequency was derived by using the total number of cytokine-producing
cells as the denominator (×100). Statistically significant differences
are described in Results.vitro priming cultures because of the secretion of IFN-g,
the in vitro priming was also carried out in the presence of
anti-IFN-g antibody. As shown in Fig. 4, the addition of
increasing concentrations of a neutralizing antibody to
IFN-g had little effect on the generation of cytokine-pro-
ducing cells from either normal peripheral blood or RASF
CD4+ T cells. Then we examined whether the combined
effects of anti-IFN-g antibody and IL-4 could influence the
effector phenotype of cells isolated from the synovium. As
shown in Table 1, Tm were isolated from matching RAPB
and RASF, and were cultured under conditions that opti-
mized the generation of IL-4-secreting effector cells [17].
RAPB Tm generated a marked increase in the percentage
of IL-4-producing cells when primed with the combination
of IL-4 and anti-IFN-g antibody. In contrast, T cells from the
synovial fluid of the same patient generated virtually no
IL-4-producing cells and few IL-2-producing cells, despite
supplemental IL-4 and anti-IFN-g antibody.
As a control, cell growth during the priming cultures was
monitored in the presence or absence of antibody to IFN-g
and IL-4. As shown in Fig. 5, synovial T-cell growth was
not inhibited by the addition of anti-IFN-g antibody or IL-4.
These data suggest that RAPB Tm have the capacity to
generate IL-4-producing or IFN-g-producing effector cells,
whereas memory T cells from RASF are inhibited in their
capacity to become IL-4-producing effector cells. Further
studies indicated that anti-CD28 mAb and cytokines
enhanced synovial fluid Tm growth approximately fourfold
above the initial input cell number. Synovial fluid T cells
cultured in medium alone underwent a fourfold reduction
in cell number, whereas cells cultured with cytokines alone
Available online http://arthritis-research.com/content/3/1/054
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Figure 3
RA synovial memory T cells are deficient in IL-4-producing cells after in vitro priming. CD4+ memory effector T cells were placed into priming
cultures to generate effector cells. Effector T cells were generated by priming in the presence of anti-CD28 mAb and cytokines, as described in
Materials and methods, or with additional immobilized anti-CD3 mAb, OKT3, at the indicated concentrations (T3lo, 0.01 mg/ml; and T3hi, 1 mg/ml).
After priming, the cells were harvested and rested in cytokines before restimulation to detect intracellular cytokines as described in Materials and
methods; 104 cells were collected for each analysis. The data shown were derived from independent experiments; for normal donors (n=4), RAPB
(n=4), RASF (n=4), and RAST (n=3), low-dose OKT3 was omitted in one experiment. The frequency of each subset of cytokine-producing cells
is shown. The total number of cytokine-producing cells in each sample is shown in the upper right corner. *P<0.05, versus freshly isolated
samples shown in Fig. 2 (two-tailed Student’s t-test).increased in number by an average of twofold (data not
shown). These data further support the conclusion that
synovial fluid T cells were responsive to signals delivered
by the combination of anti-CD28 and cytokines.
Discussion
RAST and RASF were deficient in IL-4-secreting cells as
compared with RAPB after a brief in vitro stimulation.
Thus, mature IL-4-secreting effector cells were found to
be decreased in the RA synovium but not in the blood.
There are at least three major mechanisms by which IL-4
production might be inhibited in the RA synovium. One
mechanism could be through the selective recruitment of
IFN-g-producing effector cells. For example, it has been
suggested that the T cells found in the RA synovium have
been selectively recruited on the basis of expression of
chemokine receptors [20]. Thus, T cells found in the
rheumatoid synovium express CCR5, whereas T cells
found at sites of parasitic infection express CCR4 and
CCR3 [20,21]. However, the role of chemokine receptor
expression in the recruitment of T cells to these sites is
unknown. This possibility cannot be the full explanation of
the current observations in light of the finding that synovial
tissue T cells had the capacity to differentiate into IL-4-
secreting effector cells in in vitro cultures. Thus, some syn-
ovial cells remained responsive to IL-4- and
anti-CD28-mediated signaling in the priming cultures. A
second mechanism for suppression of IL-4 production in
the rheumatoid synovium could be through regulatory
signals received in the local microenvironment. This
remains a likely possibility because studies in murine
models have shown that only the most highly differentiated
T cells obtain a polarized cytokine secretion profile that
cannot be altered by external stimuli [22]. A third possibil-
ity is that precursor cells of IL-4 producers rapidly migrate
out of the synovium, perhaps being unresponsive to reten-
tion signals.
Although the exact mechanism that is operative in the RA
synovium remains to be elucidated, our ongoing studies
are focused on determining the phenotype and response
defect of these highly polarized Th cells.
Tm isolated from rheumatoid blood or synovium contained
increased numbers of cells with the capacity to produce
IFN-g after a brief in vitro stimulation, compared with the
same subset isolated from the periphery of normal donors.
Arthritis Research    Vol 3 No 1 Davis et al
Table 1
Deficient induction of IL-4 producers from synovial precursors
Percentage of cytokine-producing cells
RAPB RASF
Addition IL-2 IL-2 + IFN-g IFN-g IL-4 IL-2 IL-2 + IFN-g IFN-g IL-4
Nil 19 24 34 2 4 27 60 0
Anti-IFN-g 23 25 28 1 7 33 47 0
IL-4 32 23 25 14 5 29 49 0
Anti-IFN-g + IL-4 41 16 20 23 4 23 54 0
CD45RO+,CD4+ memory effector T cells were obtained from RA matching peripheral blood and synovial fluid. T cells were cultured for 1 week
with OKT3 (0.01 mg/ml) and anti-CD28, as described in Materials and methods. Where indicated, the cultures contained saturating concentrations
of anti-IFN-g antibody and/or IL-4. Afterward, the cells were washed, rested for 2.5 days, and restimulated for 6 h with mitogen to assess
intracellular cytokines by flow cytometry; 104 cells were analyzed for each sample. The percentage of cytokine-expressing cells for each sample is
shown. Similar results were obtained in at least two independent experiments. No significant difference (P > 0.05) was observed in the percentage
of synovial IL-4-producing effector cells in the absence or presence of anti-IFN-g antibody and/or IL-4.
Figure 4
In vitro generation of effector cells in the presence of anti-IFN-g
antibody. CD4+ memory effector T cells obtained from the peripheral
blood of a healthy donor (normal) or from RASF (patient) were
stimulated as described in Fig. 3 with immobilized anti-CD3 mAb
(OKT3, 0.01mg/ml), anti-CD28, and cytokines. In addition, cultures
were carried out in the presence of increasing concentrations of a
neutralizing anti-IFN-g antibody as indicated. After priming, the cells
were washed, rested for 2.5 days and restimulated with mitogen to
assess intracellular cytokines; 104 cells were collected for each
analysis. The data are representative of at least two experiments. No
significant difference was observed in the presence of anti-IFN-g
antibody (P>0.05).A strong mitogenic stimulation was employed in order to
obtain the maximum cytokine-secreting potential of the
effector population. We have previously demonstrated that
staining for intracellular cytokines correlated with cytokine
secretion [17]. However, intracellular cytokine analysis
proved to be a more sensitive method for detecting
cytokines, such as IL-2 and IL-4, and also made it possible
to determine the percentage of cells producing each. It
should be noted that longer incubations did not result in a
substantial increase in the number of cytokine-secreting
cells detected in this assay. These studies corroborate
previous studies that demonstrated that synovial T cells
are enriched in IFN-g-producing cells on initial isolation
[11]. The results suggest that these memory cells appear
to have undergone biased differentiation into Th1 cells,
perhaps as a result of signals received in the synovial
microenvironment. The small increase in the number of
IFN-g-producing cells found in rheumatoid blood may well
reflect the recirculation of memory T cells previously acti-
vated in the blood [7,23].
Tm were used for these studies because it has been
shown [7,9] that the majority of CD4+ cells in the RA syn-
ovium are of the memory subset. Therefore, a potential
concern was that the in vitro priming protocol might select
for cells that are already committed to IFN-g or IL-4 pro-
duction, rather than generate new effector cells. In
humans, however, highly polarized effector T cells arise
late in the differentiation pathway [17–19]. Whereas early
memory T cells, identified by the CD45RO+,CD27+ phe-
notype, have the potential to secrete IL-2 and IFN-g, these
cells cannot produce IL-4 and few produce IFN-g in the
absence of IL-2 [17,19]. Only mature memory cells, identi-
fied by the presence of CD45RO and the loss of CD27
cell-surface expression, have the capacity to secrete IFN-g
or IL-4 alone. We have previously shown that the in vitro
priming protocol used in the present study induces the dif-
ferentiation of early uncommitted CD4+,CD27+ memory
T cells into IL-4-producing effector cells [17]. Thus, it was
hypothesized that the uncommitted early CD4+,CD27+
memory cells that were isolated from the RA synovium or
blood maintained the capacity to differentiate into IL-4-
producing effector cells. The majority of T cells that are
found in the RA synovium belong to the early memory
subset [7]. Therefore, the defective generation of IL-4 pro-
ducers from RA synovial fluid under conditions that
induced IL-4-producing effector cells from blood memory
T cells suggested that the rheumatoid microenviroment
played an important role in selecting or modifying the pre-
cursor effector memory population.
CD28 is expressed by most human T cells and is thought
to be critical for T-cell differentiation. CD28 is also impor-
tant during T-cell receptor-mediated activation, IL-2 pro-
duction, and the prevention of anergy [24]. Recent studies
[25–27] have indicated that there were increased numbers
of CD4+,CD28– T cells in the periphery and synovium of
RA patients. Therefore, the lack of expression of CD28 on
RA CD4+ T cells represented a potential explanation for
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c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Figure 5
T-cell growth in the presence of IL-4 and anti-IFN-g antibody. T cells
(0.5×106/sample) were cultured in the presence or absence of IL-4,
anti-IFN-g antibody, or both as described in Table 1. After priming, the
cells were harvested and counted to assess cell growth, as described
in Materials and methods. Similar results were obtained in at least two
experiments. No significant difference (P>0.05) was observed when
the cells were cultured in the presence of IL-4 alone or in combination
with anti-IFN-g antibody.the abnormal memory T-cell differentiation observed in RA
blood and tissue and the deficiency in IL-4-producing
effector cells from the synovial fluid after in vitro priming.
However, CD4+,CD28– cells are a minor subset of T cells,
representing less than 3% of peripheral CD4+ T cells from
the most chronically active RA patients versus less than
1% from healthy control individuals [26], and are therefore
unlikely to account for the broad defect in memory T-cell
differentiation found here. We have observed that
CD4+,CD28– cells in the periphery represent a unique
subset that is restricted to the CD4+,CD27– population
(Davis L, unpublished observation). As noted above,
although there were increased numbers of well-differenti-
ated CD4+,CD27– cells in the RA synovium, these cells
represented the minority of Tm [7]. Therefore, the inability
to modulate effector cell responses in RASF samples
could not be explained by the absence of CD28. More-
over, RASF T cells were capable of cell growth in
response to anti-CD28 mAbs and cytokines. This finding
is in agreement with previous studies [28] demonstrating
that the CD28 signaling pathway was intact in RA synovial
CD4+ T cells.
The present studies also demonstrated that synovial fluid
Tm lacked the capacity to generate IL-4-secreting effector
cells in numbers similar to those found in the periphery.
Our previous studies [17] demonstrated that IL-4 was
required during the in vitro priming cultures to generate
IL-4-producing effector cells from non-IL-4-producing early
memory precursor cells. Therefore, one concern in the
current studies was that RA T cells might require exoge-
nous IL-4 to generate IL-4-producing effector cells.
An additional concern was that IFN-g-producing effector
cells might inhibit potential IL-4 precursors from differentiat-
ing or expanding in these cultures, although previous
studies [29–31] demonstrated that IFN-g indirectly affected
the generation of IL-4-secreting cells through the activities
of antigen-presenting cells. It should be noted that antigen-
presenting cells were depleted from the memory T-cell pop-
ulation before priming in the present studies, and therefore
this possibility was only a minor concern.
Both the addition of IL-4 to the priming cultures and the
presence of anti-IFN-g antibody ensured that potential
IL-4-secreting precursor populations had optimal condi-
tions for differentiation. Blocking IFN-g activity during in
vitro priming with a neutralizing anti-IFN-g antibody had
little effect on the number of IFN-g-secreting effector cells
detected on subsequent restimulation. Moreover, the avail-
ability of IFN-g had little impact on the generation of either
subset. Thus, the inability to generate IL-4-producing
effector cells from RASF precursor cells was not simply
explained by the presence of IFN-g-producing effector
cells or the lack of a subset of fully differentiated IL-4-pro-
ducing T cells in the initial memory cell population. Recent
studies [32] have suggested that there is an intrinsic
defect in the development of IL-4-producing effector cells
in RA patients. Therefore, it is possible that the apparent
disordered differentiation of effector cells becomes more
marked at inflammatory sites such as in the rheumatoid
synovium [23,32].
It is interesting to note that both IL-2 production and IL-4
production appear to be downregulated in RASF T cells.
Previous studies [9] have shown that mature memory
(CD45RO+,CD27–) CD4+ T cells isolated from the
blood have the same capacity as early memory
(CD45RO+,CD27+) CD4+ T cells to produce IL-2. In the
RA synovium, IL-2 appears to be downregulated [9]. It
should be noted that IL-2 production was not decreased
in T cells obtained from osteoarthritic joints [9]. In addition,
Tm obtained from other tissues, such as inflamed tonsil,
expressed levels of IL-2 that were similar to those in blood
(Davis L, unpublished observation). Therefore, migration
into tissue per se does not induce downregulation of IL-2
production. Recent studies [33] have attributed the lack of
IL-2 production by synovial CD4+ T cells to a defect in the
T-cell receptor-mediated signal transduction cascade.
However, in the present studies we made use of stimuli
that bypassed the early steps in the T-cell receptor-medi-
ated signaling cascade and found that there was defective
IL-2 production in cells stimulated immediately on isolation
from the RA synovium, whereas these same cells were
completely competent for IFN-g production. Thus, it is
interesting to speculate that IL-2 and IL-4 are downregu-
lated in the rheumatoid synovium by some active repressor
mechanism induced by the synovial microenvironment.
Although recent studies have indicated that redox balance
alterations were critical in determining whether cells can
produce IL-2 [33,34], it is not known whether this influ-
ences IL-4 production, or has it been determined whether
readjustment of redox balance in RA synovial T cells could
correct the deficiency in IL-4.
Few studies have used similar techniques to assess
cytokine production in blood, synovial tissue, and synovial
fluid obtained from RA patients. Immunohistology is rou-
tinely carried out on synovial tissue sections, whereas
enzyme-linked immunosorbent assays are employed to
determine cytokine profiles of serum and synovial fluid
[9,11–13,31]. Therefore, it has remained difficult to deter-
mine the potential impact of these compartments on T-cell
function in rheumatoid inflammation. In the current studies,
RA T cells from all three compartments produced
increased amounts of IFN-g on immediate stimulation.
However, the cytokine profiles diverged when assessed
after in vitro priming. Whereas, synovial tissue Tm were
deficient in IL-4 producers compared with matching blood,
these cells retained the ability to generate IL-4-producing
effector cells. In this regard, recent studies [31] have sug-
gested that synovial tissue cells were selectively respon-
Arthritis Research    Vol 3 No 1 Davis et alsive to IL-12 produced in the synovium, because IL-12
induced increased production of IFN-g, but not IL-2 and
IL-4. Those studies support the hypothesis that the syn-
ovial microenvironment may play a role in skewing T cells
toward a Th1 phenotype. The finding that IL-4-producing
effector cells could be generated from synovial tissue
T cells once removed from that environment suggests that
all of the cells were not yet terminally polarized to Th1-like
effector cells. Importantly, synovial fluid T cells appeared
to have been more affected by the synovial microenviron-
ment than synovial tissue T cells because, regardless of
the  in vitro priming conditions, these cells yielded
increased percentages of IFN-g producers and were defi-
cient in IL-4 producers.
The present data suggest that synovial fluid T cells are
those that have passed through the synovium, whereas
synovial tissue T cells are a mixed population of recently
migrated cells and those that have been retained in the
synovium. Whether the inability of synovial fluid memory
T cells to generate IL-4 producers is the result of activa-
tion, differentiation, or prolonged exposure to the synovial
microenvironment, the data clearly indicate that a majority
of synovial fluid memory T cells appear to be polarized
IFN-g effector cells.
In summary, the present studies show that RA blood and
synovial T cells contain increased numbers of polarized
IFN-g effector cells. RA synovial T cells also demonstrated
a deficiency in the ability to generate IL-4-producing effec-
tor cells. The diminished ability to generate IL-4 effector
cells from synovial T cells in vitro suggests that the
rheumatoid microenvironment alters T-cell effector func-
tion and thereby perpetuates the chronic inflammatory
disease state.
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